Actinogen Medical Limited

ASX:ACW Voorraadrapport

Marktkapitalisatie: AU$70.5m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Actinogen Medical Beheer

Beheer criteriumcontroles 2/4

De CEO Actinogen Medical's is Steve Gourlay, benoemd in Mar2021, heeft een ambtstermijn van 3.58 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 754.11K, bestaande uit 54.7% salaris en 45.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.56% van de aandelen van het bedrijf, ter waarde A$ 2.51M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 6.8 jaar.

Belangrijke informatie

Steve Gourlay

Algemeen directeur

AU$754.1k

Totale compensatie

Percentage CEO-salaris54.7%
Dienstverband CEO3.6yrs
Eigendom CEO3.6%
Management gemiddelde ambtstermijn2.7yrs
Gemiddelde ambtstermijn bestuur6.8yrs

Recente managementupdates

Recent updates

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Apr 30
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Nov 16
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Aug 02
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth

Apr 12
We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth

We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely

Nov 28
We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Aug 09
Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Apr 07
Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Oct 24
We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

Jul 11
Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

Mar 27
We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Jan 07
How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Analyse CEO-vergoeding

Hoe is Steve Gourlay's beloning veranderd ten opzichte van Actinogen Medical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024AU$754kAU$412k

-AU$13m

Mar 31 2024n/an/a

-AU$14m

Dec 31 2023n/an/a

-AU$15m

Sep 30 2023n/an/a

-AU$13m

Jun 30 2023AU$657kAU$396k

-AU$11m

Mar 31 2023n/an/a

-AU$11m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$10m

Jun 30 2022AU$955kAU$376k

-AU$9m

Mar 31 2022n/an/a

-AU$8m

Dec 31 2021n/an/a

-AU$7m

Sep 30 2021n/an/a

-AU$6m

Jun 30 2021AU$271kAU$112k

-AU$4m

Compensatie versus markt: De totale vergoeding ($USD 520.44K ) Steve } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 313.13K ).

Compensatie versus inkomsten: De vergoeding van Steve is gestegen terwijl het bedrijf verliesgevend is.

CEO

Steve Gourlay (65 yo)

3.6yrs

Tenure

AU$754,111

Compensatie

Dr. Steven G. Gourlay, also known as Steve, MBBS (M.D.), Ph D., FRACP, M.B.A., serves as Chief Executive Officer at Actinogen Medical Limited since March 15, 2021 and as its Managing Director and Director...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Steven Gourlay
MD, CEO & Director3.6yrsAU$754.11k3.56%
A$ 2.5m
William Souter
Chief Financial Officerless than a yearAU$476.62k0.015%
A$ 10.4k
Dana Hilt
Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board1.7yrsAU$913.27kgeen gegevens
Michael Roberts
Head of Investor Relations & Corporate Communications3.4yrsgeen gegevensgeen gegevens
Paul Rolan
Head of Clinical Pharmacology & Lead Physician and Depression2.7yrsAU$191.66kgeen gegevens
Fujun Li
Head of Manufacturing1.2yrsgeen gegevensgeen gegevens
Peter Webse
Company Secretary11yrsgeen gegevensgeen gegevens

2.7yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ACW wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Steven Gourlay
MD, CEO & Director3.6yrsAU$754.11k3.56%
A$ 2.5m
Dana Hilt
Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board2.8yrsAU$913.27kgeen gegevens
George Morstyn
Independent Non-Executive Director6.8yrsAU$114.27k0.44%
A$ 311.3k
Geoffrey Edward Brooke
Independent Non-Executive Chairman7.6yrsAU$234.39k0.70%
A$ 490.2k
Colin Masters
Member of Xanamem Clinical Advisory Board9.6yrsgeen gegevensgeen gegevens
Jeffrey Cummings
Member of Xanamem Clinical Advisory Board9.6yrsgeen gegevensgeen gegevens
Malcolm McComas
Independent Non-Executive Director5.5yrsAU$114.27k0.26%
A$ 186.5k
John Harrison
Member of Depression & Cognition Clinical Advisory Board2.8yrsgeen gegevensgeen gegevens
Craig Ritchie
Chairman of Xanamem Clinical Advisory Board9.6yrsgeen gegevensgeen gegevens
Jonathan Seckl
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Brian Walker
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Scott Webster
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

6.8yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ACW wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).